Share: Facebook Twitter LinkedIn
Activity Provided By:

The France Foundation

How Can We Know that a Biosimilar will be as Safe and Effective as the Reference Product?

Access Activity

Overview / Abstract:

As biosimilar guidance evolves in the United States and these biologics are studied and FDA-approved for use, it will be important for clinicians to understand how biosimilars’ characteristics overlap with, and differ from, other available biologic therapies, so that effective treatment selection and monitoring, and related patient education, can be achieved.

Expiration

Sep 29, 2017

Credits / Hours

30 Minutes

Accreditation

ACCME, ACPE

Presenters / Authors / Faculty

Andrew D. Zelenetz, MD, PhD
Vice Chair, Medical Informatics
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Edward Li, PharmD, MPH, BCOP
Associate Professor
University of New England College of Pharmacy
Portland, Maine

Jonathan Kay, MD
Professor of Medicine
University of Massachusetts Medical School
Worcester, Massachusetts

Activity Specialities / Related Topics

Dermatology, Family Medicine, Gastroenterology / GI, Hematology, Nephrology, Oncology / Cancer / Radiation Therapy, Rheumatology / Arthritis

Sponsors / Supporters / Grant Providers

Pfizer

Keywords / Search Terms

The France Foundation Biosimilars Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map